April 1, 2026
Anixa Biosciences Inc.
ISIN: US03528H1095
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 with Selection of Cytovance Biologics for cGMP Manufacturing
Follows positive Phase 1 results with 74% of participants demonstrating protocol-defined immune responses SAN JOSE, Calif., April 1, 2026 -- Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology...
Read more >>Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
Notice of Allowance marks first Korean patent covering Anixa’s breast cancer vaccine platform Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater concentrations of younger...
Read more >Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data SAN JOSE, Calif., March 2, 2026 – Anixa Biosciences, Inc....
Read more >Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limiting toxicities supports escalation to doses up to 100x higher Trial expansion reflects growing confidence in intra-peritoneal CAR-T delivery...
Read more >Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
SAN JOSE, Calif., February 2, 2026 – Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that...
Read more >Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology
Notice of Allowance marks first Mexican patent to be issued on Anixa Breast Cancer Vaccine Expands global intellectual property coverage in markets with greater late-stage breast cancer diagnoses and higher triple-negative...
Read more >Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
SAN JOSE, Calif., December 15, 2025 -- Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that...
Read more >Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Vaccine Was Safe and Well Tolerated at the Maximum Tolerated Dose Results Support Advancement of the Program into Phase 2 Development Combination of Keytruda® and the vaccine generated T cell responses and...
Read more >Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
SAN JOSE, Calif., December 10, 2025 – Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that...
Read more >Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization SAN JOSE, Calif., November 17,...
Read more >